Viewing Study NCT02955069

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:57 PM
Ignite Modification Date: 2026-02-23 @ 8:09 PM
Study NCT ID: NCT02955069
Status: COMPLETED
Last Update Posted: 2021-04-12
First Post: 2016-11-02
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Well-differentiated Non-functional NET of Thoracic Origin View
None Well-differentiated Non-functional NET of Gastrointestinal Origin View
None Well-differentiated Non-functional NET of Pancreatic Origin View
None Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Advanced or metastatic View
None NET View
None pNET View
None GI NET View
None thoracic NET View
None GEP-NEC View